See more : Koukandekirukun, Inc. (7695.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bafna Pharmaceuticals Limited (BAFNAPHARM.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bafna Pharmaceuticals Limited, a leading company in the industry within the sector.
- Yangarra Resources Ltd. (YGR.TO) Income Statement Analysis – Financial Results
- HUB Security (HUB.TA) Income Statement Analysis – Financial Results
- Radiant Innovation Inc. (3373.TWO) Income Statement Analysis – Financial Results
- Team, Inc. (TISI) Income Statement Analysis – Financial Results
- Invesco Bond Income Plus Limited (BIPS.L) Income Statement Analysis – Financial Results
Bafna Pharmaceuticals Limited (BAFNAPHARM.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 1.15B | 851.40M | 712.18M | 424.73M | 436.27M |
| Cost of Revenue | 977.94M | 714.22M | 622.35M | 405.43M | 471.43M |
| Gross Profit | 175.56M | 137.18M | 89.83M | 19.29M | -35.16M |
| Gross Profit Ratio | 15.22% | 16.11% | 12.61% | 4.54% | -8.06% |
| Research & Development | 15.21M | 14.73M | 13.59M | 10.10M | 7.53M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 51.34M | 72.14M | 17.70M | 28.56M | 119.61M |
| Other Expenses | -5.08M | 14.67M | 0.00 | -463.00K | -2.05M |
| Operating Expenses | 71.63M | 72.20M | 31.29M | 39.12M | 129.19M |
| Cost & Expenses | 1.05B | 786.42M | 653.63M | 444.55M | 600.61M |
| Interest Income | 445.00K | 336.00K | 395.00K | 394.00K | 2.50M |
| Interest Expense | 20.38M | 7.94M | 7.42M | 955.00K | 21.27M |
| Depreciation & Amortization | -53.34M | -54.93M | -44.78M | -32.67M | -34.76M |
| EBITDA | 157.27M | 119.92M | 103.33M | 12.84M | -129.58M |
| EBITDA Ratio | 13.63% | 14.08% | 14.51% | 3.02% | -29.70% |
| Operating Income | 103.92M | 64.98M | 58.55M | -19.82M | -164.35M |
| Operating Income Ratio | 9.01% | 7.63% | 8.22% | -4.67% | -37.67% |
| Total Other Income/Expenses | 12.24M | -12.82M | -279.00K | 1.04M | -18.58M |
| Income Before Tax | 116.16M | 52.16M | 58.27M | -18.78M | -182.93M |
| Income Before Tax Ratio | 10.07% | 6.13% | 8.18% | -4.42% | -41.93% |
| Income Tax Expense | 2.78M | -336.00K | -395.00K | -394.00K | 10.67M |
| Net Income | 113.38M | 52.16M | 58.27M | -18.78M | -198.80M |
| Net Income Ratio | 9.83% | 6.13% | 8.18% | -4.42% | -45.57% |
| EPS | 4.79 | 2.21 | 2.46 | -7.94 | -8.40 |
| EPS Diluted | 4.79 | 2.21 | 2.46 | -7.94 | -8.40 |
| Weighted Avg Shares Out | 23.66M | 23.66M | 23.66M | 2.37M | 23.66M |
| Weighted Avg Shares Out (Dil) | 23.66M | 23.66M | 23.66M | 2.37M | 23.66M |
Source: https://incomestatements.info
Category: Stock Reports